These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37042596)

  • 41. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
    Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
    Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
    Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Squire IB; MacFayden RJ; Reid JL; Devlin A; Lees KR
    J Cardiovasc Pharmacol; 1996 May; 27(5):657-66. PubMed ID: 8859935
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analytical lifecycle management for comprehensive and universal nitrosamine analysis in various pharmaceutical formulations by supercritical fluid chromatography.
    Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
    J Pharm Biomed Anal; 2021 Apr; 197():113960. PubMed ID: 33626447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy.
    Charoo NA; Dharani S; Khan MA; Rahman Z
    AAPS PharmSciTech; 2023 Feb; 24(2):60. PubMed ID: 36759424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tolerance to ACE inhibitors after cardiac surgery.
    Manché A; Galea J; Busuttil W
    Eur J Cardiothorac Surg; 1999 Jan; 15(1):55-60. PubMed ID: 10077374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease.
    Yamada K; Uchida S; Takahashi S; Takayama M; Nagata Y; Suzuki N; Shirakura S; Kanda T
    Brain Res; 2010 Sep; 1352():176-86. PubMed ID: 20627092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LC-MS/MS Investigation of nitrosamine impurities in certain Sartan group medicinal products available in Istanbul, Türkiye.
    Öncü T; Yüksel B; Binay E; Şen N
    Ann Pharm Fr; 2024 Jan; 82(1):72-83. PubMed ID: 37567559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
    Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
    Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ACE inhibitors in heart failure--switching from enalapril to perindopril.
    Masuell M; Brusca G; Pardo A; Piñeiro D; Checkerdhemian S; Forcada P
    Curr Med Res Opin; 2002; 18(5):296-302. PubMed ID: 12240792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
    Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
    J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.
    Schmidtsdorff S; Schmidt AH
    J Pharm Biomed Anal; 2019 Sep; 174():151-160. PubMed ID: 31174128
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
    Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
    Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease.
    Krysiak R; Sierant M; Marek B; Okopień B
    Endokrynol Pol; 2010; 61(6):683-90. PubMed ID: 21104642
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging.
    Zheng J; Brookes A; Moser J; Pfeffer H; Smith A
    J Pharm Sci; 2023 Sep; 112(9):2321-2325. PubMed ID: 37478970
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential efficacy of perindopril and enalapril in experimental diabetic nephropathy.
    Duggan KA; Hodge G; Makarious MM; Charlesworth JA
    Clin Exp Pharmacol Physiol; 1996; 23(6-7):608-10. PubMed ID: 8800600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tolerability of risk: A commentary on the nitrosamine contamination issue.
    Elder DP; Johnson GE; Snodin DJ
    J Pharm Sci; 2021 Jun; 110(6):2311-2328. PubMed ID: 33705731
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contamination of some fermented Nigerian beverages by carcinogenic nitrosamines.
    Maduagwu EN; Joaquim KA; Bassir O
    Trop Geogr Med; 1979 Jun; 31(2):283-90. PubMed ID: 505559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure.
    Krysiak R; Okopień B
    Pharmacol Rep; 2011; 63(5):1151-61. PubMed ID: 22180357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.